Literature DB >> 9614489

Potassium channel down-regulation in heart failure.

M Näbauer1, S Kääb.   

Abstract

Prolongation of action potential duration is the most consistent electrophysiological abnormality in myocardium and myocytes from hypertrophied and failing hearts. Measurements of currents in myocytes from hypertrophied and failing hearts indicate that, in most cases, this is due to a decrease in outward potassium currents. If present, a calcium-independent transient outward current is usually substantially reduced, but delayed rectifier and inward rectifier currents have also been found to be diminished. There is increasing evidence that potassium current down-regulation contributes significantly to the enhanced lability of the repolarization process in heart failure, predisposing to early after-depolarizations, dispersion of repolarization and ventricular arrhythmias. The reduction of outward potassium currents may also be involved in the enhanced sensitivity of failing myocardium to triggering factors like hypokalemia, ischemia, and antiarrhythmic agents with Class III effects. A thorough understanding of the mechanisms of cardiac excitability and arrhythmogenesis at the cellular and molecular level under normal and pathological conditions will be essential for the development of new pharmacological strategies to prevent sudden cardiac death in heart failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614489     DOI: 10.1016/s0008-6363(97)00274-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  57 in total

Review 1.  Impact of recent molecular studies on evaluation of ventricular arrhythmias.

Authors:  D M Roden
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  Relationship between transient outward K+ current and Ca2+ influx in rat cardiac myocytes of endo- and epicardial origin.

Authors:  T Volk; T H Nguyen; J H Schultz; H Ehmke
Journal:  J Physiol       Date:  1999-09-15       Impact factor: 5.182

Review 3.  Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium.

Authors:  J M Nerbonne
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

4.  Transmural differences in rat ventricular protein kinase C epsilon correlate with its functional regulation of a transient cardiac K+ current.

Authors:  K S Thorneloe; X F Liu; M P Walsh; Y Shimoni
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

5.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

6.  Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin.

Authors:  B C Knollmann; B E Knollmann-Ritschel; N J Weissman; L R Jones; M Morad
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

Review 7.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 8.  A multidimensional sight on cardiac failure: uncovered from structural to molecular level.

Authors:  Vijay Urmaliya; Gustavo Franchelli
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

9.  Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.

Authors:  Péter Biliczki; László Virág; Norbert Iost; Julius Gy Papp; András Varró
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  KChIP2 attenuates cardiac hypertrophy through regulation of Ito and intracellular calcium signaling.

Authors:  Hongwei Jin; Lahouaria Hadri; Julieta Palomeque; Charlotte Morel; Ioannis Karakikes; Roger Kaprielian; Roger Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2010-01-04       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.